Roltotatug vedotin

维洛沃妥塔单抗

Report date: 2026/04/17 11:15:16

Base Information

Drug NameRoltotatug vedotin

Drug Alias NameTORL-4-500

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker

Mechanisms of ActionProtein delta homolog 1 inhibitorsTubulin inhibitors

TargetsProtein delta homolog 1Tubulin

Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTorl Biotherapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesTorl Biotherapeutics LLC

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A